Search Results - "Stieglmaier, J."

PHASE I STUDY OF THE CD19/CD3 HALF‐LIFE EXTENDED BITE ® MOLECULE AMG 562 IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA by Mead, M. D., Popplewell, L. L., Subklewe, M., Ghobadi, A., Kuruvilla, J., Kimball, A., Tuglus, C., Agarwal, S., Stieglmaier, J.

Get full text

A FIRST‐IN‐HUMAN STUDY OF A HALF‐LIFE EXTENDED CD19‐TARGETING BiTE IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA OR FOLLICULAR LYMPHOMA by Popplewell, L., Verhoef, G., Kuruvilla, J., Tuglus, C., Kischel, R., Stieglmaier, J., Ghobadi, A.

Get full text

A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells by SCHWEMMLEIN, M, STIEGLMAIER, J, FEY, G. H, KELLNER, C, PEIPP, M, SAUL, D, ODUNCU, F, EMMERICH, B, STOCKMEYER, B, LANG, P, BECK, J. D

“…CD19 is a B-lineage-specific transmembrane signaling protein participating in the control of proliferation and differentiation. It is present at high surface…”
Get full text

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia by Gökbuget, Nicola, Dombret, Hervè, Ribera, Jose-Maria, Fielding, Adele K, Advani, Anjali, Bassan, Renato, Chia, Victoria, Doubek, Michael, Giebel, Sebastian, Hoelzer, Dieter, Ifrah, Norbert, Katz, Aaron, Kelsh, Michael, Martinelli, Giovanni, Morgades, Mireia, O'Brien, Susan, Rowe, Jacob M, Stieglmaier, Julia, Wadleigh, Martha, Kantarjian, Hagop

“…Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To…”
Get full text

264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) by Kelly, W.K., Danila, D.C., Lin, C-C., Lee, J-L., Matsubara, N., Ward, P.J., Armstrong, A.J., Pook, D.W., Kim, M., Dorff, T., Fischer, S., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Jurida, G., Connarn, J., Penny, H., Stieglmaier, J., Appleman, L.J.

Get full text

1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) by Kelly, W., Danila, D., Lin, C-C., Lee, J-L., Matsubara, N., Ward, P., Armstrong, A.J., Pook, D., Kim, M., Dorff, T., Fischer, S., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Jurida, G., Connarn, J., Penny, H., Stieglmaier, J., Appleman, L.J.

Get full text

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells by Kellner, Christian, Bruenke, Joerg, Stieglmaier, Julia, Schwemmlein, Michael, Schwenkert, Michael, Singer, Heiko, Mentz, Kristin, Peipp, Matthias, Lang, Peter, Oduncu, Fuat, Stockmeyer, Bernhard, Fey, Georg H

“…A novel bispecific antibody-derived recombinant protein targeting leukemias and lymphomas was designed, a single-chain Fv triple body (sctb) consisting of 1…”
Get full text

Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies by BARBIN, Karin, STIEGLMAIER, Julia, SAUL, Domenica, STIEGLMAIER, Kristin, STOCKMEYER, Bernhard, PFEIFFER, Matthias, LANG, Peter, FEY, Georg H

“…To investigate the influence of N-linked oligosaccharides at asparagines-297 on the cytolytic potential of chimeric CD19 antibodies, three distinct variants…”
Get full text

Selective induction of apoptosis in leukemic Blymphoid cells by a CD19-specific TRAIL fusion protein by Stieglmaier, J, Bremer, E, Kellner, C, Liebig, T M, Cate, B T, Peipp, M, Schulze-Koops, H, Pfeiffer, M, Buehring, H-J, Greil, J, Oduncu, F, Emmerich, B, Fey, G H, Helfrich, W

“…Although the treatment outcome of lymphoid malignancies has improved in recent years by the introduction of transplantation and antibody-based therapeutics,…”
Get full text